Philosophy of Care
Dr. Evans' philosophy of care is to:
- fully assess the patient's medical condition, including how it relates to family and social circumstances;
- educate the patient fully about their disease process; and
- include the patient in the decision-making process that best suits the outcomes they seek.
In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.
Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy.
His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders.
Dr. Evans also has expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.
Dr. Evans' research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor.
His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.
B.A., University of Vermont, Burlington VT 1981
University of California, San Francisco, San Francisco CA 1991-1995
University of Texas, Anderson Cancer Center, Houston TX 1995-1997
American College of Surgeons, 2000
National Board of Medical Examiners, 1987
American Association for the Advancement of Science
American Association of Genitourinary Surgeons
American College of Surgeons
American Society of Clinical Oncology
American Urology Association
Association of Military Surgeons of the United States
European Association of Urology
Society for Basic Urologic Research
Society of Government Urologists
Society of Urologic Oncology
Southwest Oncology Group
Uniformed Services University
Select Honors and Awards:
American Association of Genitourinary Surgeons, Elected Membership, 2009
Western Section AUA nominee for the Gold Cystoscope Award, 2005
1st Prize, Joseph F. McCarthy Essay Contest of the American Urological Association, 2003
Finalist, California Cancer Research Program Gerald P. Murphy Award, 2001
Honorable Mention, AUA Circon/ACMI Essay Contest, Laboratory Research, 1996
First Place Award for Basic Science, Society for University Urology Residents, National Chief Resident Meeting, 1995
Recipient, American Association for Cancer Research Young Investigator Award, ?Basic and Clinical Aspects of Prostate Cancer?, 1994
Recipient, American Association for Cancer Research/National Cancer Institute Travel Grant, Molecular Biology, Aspen, CO, 1993
Recipient, Army Commendation Medal, 1990
Finalist, Army Science Conference Competition, 1990
Select Recent Publications:
To view a detailed list of Dr. Evans' publications, please click here.
Chan Y, Fisher P, Tilki D, Evans CP. Urethral recurrence after cystectomy: current preventative measures, diagnosis and management. BJU Int. 2016 Apr;117(4):563-9.
Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 Mar 28. [Epub ahead of print]
Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 Mar 28. [Epub ahead of print]
Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Mar 19.[Epub ahead of print]
Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res. 2015 Dec 15;75(24):5309-17.
Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 1;13:206.
Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug;194(2):304-8.
Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015 Apr 1;75(7):1413-22.
Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget. 2014 Sep 15;5(17):7217-59. Review.
Farrow JM, Yang JC, Evans CP. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014 Sep;11(9):508-16.